In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV).

On October 23, 2019, Dr. George Church visited Qihan, and he learned about the team’s research progress and gave a scientific speech on cutting-edge gene-editing technology.

MIT Technology Review released their list of the "50 Smartest Companies in China 2019" . Qihan Bio was named on the TR50 list.